Evoke Pharma to present new data comparing TD receiving OCMP treatment

Evoke Pharma (EVOK) announced that a new abstract comparing the incidence of tardive dyskinesia, TD, in patients receiving continuous versus intermittent oral metoclopramide, OMCP, treatment has been accepted for presentation at Digestive Disease Week, DDW, 2025, taking place May 3-6, 2025, in San Diego, CA. The analysis leverages real-world data from over 100 million U.S. patients and highlights differences in TD incidence rates and timing based on metoclopramide dosing patterns. “This research builds on our ongoing commitment to understanding metoclopramide’s long-term safety profile,” said Matt D’Onofrio, CEO of Evoke Pharma. “As the only FDA-approved treatment for diabetic gastroparesis, it’s critical that we continue evaluating both efficacy and safety, particularly around concerns like tardive dyskinesia. This real-world data helps clarify risk profiles and supports more informed prescribing decisions for physicians interested in Gimoti. We’re excited to share these findings with the DDW community.”